Trials / Completed

CompletedNCT00366262

Study Evaluating the Gastrointestinal Safety of PLA-695 Compared to Placebo and Naproxen

A Randomized, Double-Blind, Parallel Group Study To Compare The 7-Day Gastrointestinal Safety of 2 Doses of PLA-695 To That Of Placebo And Naproxen

Status: Completed
Phase: Phase 1
Study type: Interventional
Enrollment: —

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
Sex: All
Age: 18 Years – 60 Years
Healthy volunteers: Accepted

Summary

The purpose of this study is to provide an initial assessment of the gastrointestinal safety of a 7-day regimen of PLA-695 compared to placebo or naproxen.

Conditions

Healthy

Interventions

Type	Name	Description
DRUG	PLA-695
DRUG	Naproxen
DRUG	Placebo

Timeline

Start date: 2006-06-01
Completion: 2007-03-01
First posted: 2006-08-21
Last updated: 2008-08-05

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00366262. Inclusion in this directory is not an endorsement.